Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Loos

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|January 22, 2004
Factors affecting pharmacokinetic variability of oral topotecan: a population analysisF Léger, W J Loos, J Fourcade, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 29, 1999
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysisA Sparreboom, M J de Jonge, C J Punt, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|April 25, 2000
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatographyW J Loos, D Kehrer, E Brouwer, et al.
British Journal of Cancer|May 21, 2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg, N Steeghs, W J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.
Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij ratsJ H Schellens, W Van de Vrie, W J Loos, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|January 22, 2004
Factors affecting pharmacokinetic variability of oral topotecan: a population analysisF Léger, W J Loos, J Fourcade, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 29, 1999
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysisA Sparreboom, M J de Jonge, C J Punt, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|April 25, 2000
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatographyW J Loos, D Kehrer, E Brouwer, et al.
British Journal of Cancer|May 21, 2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg, N Steeghs, W J Loos, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2003
Influence of the cisplatin hydration schedule on topotecan pharmacokineticsH Gelderblom, W J Loos, A Sparreboom, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2006
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumorsA Felici, W J Loos, J Verweij, et al.
Cancer Research|April 10, 1999
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsA Sparreboom, L van Zuylen, E Brouwer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij ratsJ H Schellens, W Van de Vrie, W J Loos, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 7, 2007
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxelW J Loos, W C Zamboni, F K Engels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2001
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposureF E de Jongh, J Verweij, W J Loos, et al.
Pageof 7